Actively Recruiting
Bronchodilators and Lung Mechanics During Exercise in COPD
Led by Dr. J. Alberto Neder · Updated on 2025-02-13
25
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bronchodilators are medications that open the bronchi to help patients with COPD to breathe better. It is still not known exactly how this effect improves shortness of breath in people with COPD. The goal of this clinical trial is to determine whether bronchodilators lower resistance in the smallest airways in the lungs, and whether this will improve the feeling of breathlessness in these patients. The main questions the investigators attempt to answer are: * In patients with COPD, does treatment with a short-acting bronchodilator improve small airway resistance during exercise? * In patients with COPD, does acute treatment with short-acting bronchodilator improve breathlessness and exercise endurance? The investigators will compare short-acting bronchodilators to placebo (a substance that contains no drug) to see if the bronchodilator medications improve small airway resistance and breathlessness during exercise. Participants will: * Visit the research laboratory 3 visits to complete tests of lung function and exercise * Complete 2 identical visits (Visit 2 and 3), one in which the participant receives bronchodilator and one in which the participant receives placebo.
CONDITIONS
Official Title
Bronchodilators and Lung Mechanics During Exercise in COPD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of COPD
- Male or female aged 40 years or older
- Current or former smokers with at least 20 pack-year history
- Forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio below lower limit of normal
- At least 10% predicted increase in FVC after inhaling 400 mcg salbutamol
- Functional residual capacity 120% predicted or above and/or above upper limit of normal
- Modified Medical Research Council dyspnea scale score of 2 or higher
- Clinically stable with no exacerbations in the past 6 weeks
- Able to give informed consent and complete all study procedures
You will not qualify if you...
- Major heart or lung diseases other than COPD, including asthma, interstitial lung disease, pulmonary hypertension, and congestive heart failure
- Neuromuscular or musculoskeletal disorders
- Use of daytime oxygen or oxygen desaturation below 80% during exercise on room air
- Any other condition causing breathlessness or exercise intolerance
- Any reason that prevents safe cardiopulmonary exercise testing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Respiratory Investigation Unit, Kingston Health Sciences Center
Kingston, Ontario, Canada, K7L 2V6
Actively Recruiting
Research Team
J
J Alberto Neder Serafini, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here